Pricing Log in Create free account
Friday 6 November 2026 Export CRON’s income statement to Excel — free account

Cronos Group Inc.

CRON Healthcare Drug Manufacturers Specialty & Generic

Cronos Group Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.6 million, up 24.6% from fiscal 2024.

Revenue
+74.6%
EPS
−42.9%
Free cash flow
+179.6%
Total debt
−21.8%

Quarter to September 2026, against a year earlier

3.72 0.21 +5.98%
Market cap
$1.4B
P/E
21.9×
Fwd P/E
19.5×
Dividend yield
—
F-score
5/9
Altman Z
12.67
Beneish M
−2.05
Dividend safety
20/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 50.54%

Capital & Financial Ratios $m

Size
Market Cap 1,370.00
Revenue ttm 206.20
Net income ttm 68.71
Free cash flow ttm 65.38
Net debt Q (744.09)
Valuation
P/E 21.88
Forward P/E 19.50
Price / sales 6.65
Forward P/S Powerpack
Price / FCF 21.09
Price / book 1.22
Financial health
Current ratio Q 12.71 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 0.21
Growth
Revenue growth Q +74.61% (above 0%: growing)
Operating income growth Q +1,894.43% (above 0%: growing)
EPS, this year +940.00% (at or above 15%: strong)
EPS, next year A +8.33%
Revenue, next year A +28.64% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +2.94%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.0×, against a ten-year median of 3.0×; over the ten years it ranged from −2.1× in 2023 to 392× in 2018.
P/E against its own 10 years 56.34%
10-year low 10-year high
P/S against its own 10 years 12.72%
10-year low 10-year high
P/B against its own 10 years 56.20%
10-year low 10-year high
EV/Sales against its own 10 years 36.21%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 862 859 832 745
Receivables 30 29 57 —
Inventory 30 33 47 55
Other — — — —
933 936 944 859
2023 2024 2025 Q'26
Payables 12 17 12 16
ST’ Debt — — — —
Other 0 0 — —
41 50 48 68

Compound Annual Growth %

10y 5y 3y
Sales — 25.70% 19.11%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (7.72%) 0.06%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.01 Actual 0.03

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.00 0.07 Beat by 0.07
Q4 FY25 0.01 0.00 Miss by 0.01
Q1 FY26 0.01 0.01 Met by 0.00
Q2 FY26 0.01 0.03 Beat by 0.02
Q3 FY26 0.03 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.04 0.09 0.04 — —
’25 0.02 (0.10) 0.07 0.00 (0.02)
’24 (0.01) (0.02) 0.02 0.11 0.11
’23 (0.05) (0.02) 0.00 (0.12) (0.19)
’22 (0.09) (0.05) (0.10) (0.21) (0.45)
’21 (0.44) 0.15 0.21 (0.36) (1.07)
’20 0.20 (0.31) 0.19 (0.31) (0.21)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 45 53 63 — —
’25 32 33 36 45 147
’24 25 28 34 30 118
’23 19 19 25 24 87
’22 25 22 20 20 87
’21 13 16 20 26 74
’20 8 10 11 17 47
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 11 24 34 — —
’25 (2) 3 13 12 26
’24 (2) 2 12 8 19
’23 (48) (12) 0 17 (43)
’22 (34) (17) (13) (24) (89)
’21 (47) (40) (31) (36) (154)
’20 (39) (39) (28) (38) (145)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 9 22 24 — —
’25 (17) (1) 9 10 0
’24 (4) 1 5 4 6
’23 (48) (12) (1) 15 (46)
’22 (35) (19) (15) (25) (94)
’21 (54) (42) (34) (37) (166)
’20 (46) (48) (36) (49) (180)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 3 12 24 47 74 87 87 118 147 206 +91.7% 189 178 231 +16.4%
Gross margin, % 359.64 177.12 51.26 (74.09) (55.29) (23.56) 17.79 13.65 21.42 42.81 46.59 (316.8) pt
EBT (1) 2 (22) 1,166 (73) (397) (121) (74) 37 (17) 60 +32.9%
EBT margin, % (317.25) 68.32 (179.99) 4,909.21 (156.84) (533.53) (139.49) (84.44) 31.11 (11.68) 29.19 +305.6 pt
Net income (1) 2 (22) 1,166 (75) (397) (169) (75) 40 (3) 69 +14.0%
Per share, $
Per share, $ Revenue 0.01 0.02 0.07 0.08 0.13 0.20 0.23 0.23 0.31 0.38 0.56 +60.9%
Earnings (0.01) 0.01 (0.13) 3.76 (0.21) (1.07) (0.45) (0.19) 0.11 (0.02) 0.17 +8.0%
Cash flow (0.06) (0.03) (0.04) (0.42) (0.41) (0.41) (0.24) (0.11) 0.05 0.07 0.22 n/m
Capex (0.01) (0.24) (0.51) (0.13) (0.10) (0.03) (0.01) (0.01) (0.03) (0.07) (0.04) +18.5%
Free cash flow (0.08) (0.28) (0.56) (0.55) (0.51) (0.45) (0.25) (0.12) 0.01 0.00 0.18 (42.9%)
Book value 0.33 0.49 0.86 5.64 4.86 3.60 3.03 2.88 2.91 2.98 3.05 +27.9%
Shares, m 78 135 172 310 352 370 377 381 382 383 376 +19.3%
Valuation, ×
Valuation, × P/E 215.15 814.14 0.00 1.93 0.00 0.00 0.00 0.00 19.52 0.00 21.88 105.1
P/S 0.00 345.06 147.67 100.14 52.23 19.51 10.86 9.21 6.56 6.88 6.65 69.8
P/B 7.39 16.31 12.05 1.36 1.43 1.09 0.83 0.73 0.69 0.88 1.22 4.3
EV/Sales 0.00 344.34 145.70 37.01 24.80 6.10 0.78 (0.64) (0.73) 1.21 3.04 55.9
EV/FCF 0.00 (29.13) (18.38) (5.19) (6.43) (2.74) (0.72) 1.20 (15.12) (936.49) 9.65 (101.3)
Cash, $m
Cash, $m Operating cash flow (5) (4) (8) (130) (145) (154) (89) (43) 19 26 81 n/m
Capex (1) (33) (89) (39) (35) (12) (5) (3) (13) (26) (16) +41.4%
Free cash flow (6) (37) (96) (169) (180) (166) (94) (46) 6 0 65 (31.9%)
Balance, $m
Balance, $m Working capital 0 15 7 1,240 1,165 1,025 892 892 886 896 792 +149.2%
Net debt 0 (3) (24) (1,499) (1,281) (998) (875) (860) (858) (831) (744) n/m
Shareholders’ equity 25 67 149 1,749 1,708 1,334 1,141 1,096 1,111 1,143 1,125 +52.6%
Returns, %
Returns, % ROA (1.52) 3.48 (16.55) 102.60 (3.64) (23.84) (12.93) (6.29) 3.56 (0.80) 4.87 +0.7 pt
ROIC (3.89) (1.60) (10.70) (30.32) (26.26) (36.55) (25.38) (22.44) (18.89) (3.34) 1.28 +0.5 pt
ROE (1.91) 4.17 (20.11) 122.95 (4.23) (26.04) (13.63) (6.61) 3.72 (0.84) 5.12 +1.1 pt
People
People Employees 74 148 291 631 665 626 447 356 459 610 — +26.4%
Revenue/emp, $m 0.01 0.02 0.04 0.04 0.07 0.12 0.19 0.25 0.26 0.24 — +51.7%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Cronos Group Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
XERS Xeris Biopharma Holdings, Inc. $2.4B — (loss-making) — (loss-making) +44.16% (above 0%: growing) +1,478.95% (above 0%: growing) +93.18% (above 0%: growing) 88.41% 15.78% Compare
ALVO Alvotech $1.8B — (loss-making) 111× +2,310.95% (above 0%: growing) −99.51% (below 0%: shrinking) −496.58% (below 0%: shrinking) 56.47% 9.14% Compare
ANIP ANI Pharmaceuticals, Inc. $1.6B 13.3× 14.3× +27.64% (above 0%: growing) +29.41% (above 0%: growing) +85.49% (above 0%: growing) 61.64% 18.01% Compare
PCRX Pacira BioSciences, Inc. $1.5B 38.4× 56.6× −1.59% (below 0%: shrinking) +500.00% (above 0%: growing) −18.47% (below 0%: shrinking) 0.00% 12.61% Compare
PAHC Phibro Animal Health Corporation $1.4B 14.0× 12.6× +6.29% (above 0%: growing) +12.31% (above 0%: growing) +262.08% (above 0%: growing) 33.23% 12.83% Compare
CRON Cronos Group Inc. $1.4B 21.9× 19.5× +74.61% (above 0%: growing) −42.86% (below 0%: shrinking) +179.64% (above 0%: growing) 50.88% 14.23%
ETON Eton Pharmaceuticals, Inc. $1.4B 26.8× 48.0× +157.91% (above 0%: growing) n/m +172.55% (above 0%: growing) 76.48% 39.73% Compare
AMPH Amphastar Pharmaceuticals, Inc. $1.2B 12.3× 12.8× +8.22% (above 0%: growing) +134.21% (above 0%: growing) −29.38% (below 0%: shrinking) 47.99% 24.46% Compare
HROW Harrow, Inc. $976.2M — (loss-making) — (loss-making) +10.85% (above 0%: growing) n/m −838.78% (below 0%: shrinking) 71.27% (15.58%) Compare
Median of peers $1.4B 14.0× 31.2× +19.24% +81.81% +33.51% 59.05% 14.31%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 24 April 2026

Ownership

Directors and executive officers, together 7.80%
Altria Group, Inc. 41.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Cronos Group Inc. (CRON) Latest News

6 Nov

Impact 3 · · GuruFocus.com

5 Nov

Impact 3 · · MarketBeat transcript
Impact 3 · · GlobeNewswire

29 Oct

Impact 3 · · Barchart

27 Oct

Impact 3 · · Simply Wall St.

26 Oct

Impact 3 · · Simply Wall St.
Impact 3 · · Zacks

25 Oct

Impact 4 · · Simply Wall St.

23 Oct

Impact 3 · · Zacks

15 Oct

Impact 4 · · GlobeNewswire

13 Oct

Impact 3 · · GlobeNewswire

9 Oct

Impact 4 · · Zacks

5 Oct

Impact 3 · · Simply Wall St.

28 Sep

Impact 4 · · Investing.com

24 Sep

Impact 4 · · MarketBeat
Impact 3 · · GlobeNewswire

22 Sep

Impact 4 · · Simply Wall St.
Impact 4 · · The Motley Fool

14 Sep

Impact 3 ·

2 Sep

Impact 3 ·

6 Aug

Impact 4 · transcript
Impact 3 ·
Impact 3 · · MarketBeat transcript
Impact 3 ·
Impact 3 ·

21 Jul

Impact 3 ·

24 Jun

Impact 3 · · Zacks

16 Jun

Impact 3 ·

11 Jun

Impact 3 ·

31 May

Impact 3 · · Insider Monkey
stockrow.com/CRON · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com